275 related articles for article (PubMed ID: 17024118)
1. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma.
Fonseca R; Van Wier SA; Chng WJ; Ketterling R; Lacy MQ; Dispenzieri A; Bergsagel PL; Rajkumar SV; Greipp PR; Litzow MR; Price-Troska T; Henderson KJ; Ahmann GJ; Gertz MA
Leukemia; 2006 Nov; 20(11):2034-40. PubMed ID: 17024118
[TBL] [Abstract][Full Text] [Related]
2. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma.
Shaughnessy J
Hematology; 2005; 10 Suppl 1():117-26. PubMed ID: 16188652
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of CKS1B mRNA expression and copy number gain in patients with plasma cell disorders.
Stella F; Pedrazzini E; Baialardo E; Fantl DB; Schutz N; Slavutsky I
Blood Cells Mol Dis; 2014 Sep; 53(3):110-7. PubMed ID: 24973170
[TBL] [Abstract][Full Text] [Related]
4. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
Chen MH; Qi C; Reece D; Chang H
Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation.
Chang H; Qi X; Trieu Y; Xu W; Reader JC; Ning Y; Reece D
Br J Haematol; 2006 Nov; 135(4):486-91. PubMed ID: 16995883
[TBL] [Abstract][Full Text] [Related]
6. Increased copy number of the interleukin-6 receptor gene is associated with adverse survival in multiple myeloma patients treated with autologous stem cell transplantation.
Kim SY; Min HJ; Park HK; Oh B; Kim TY; She CJ; Hwang SM; Kim M; Kim HK; Kim I; Yoon SS; Park S; Kim BK; Lee JH; Lee DS;
Biol Blood Marrow Transplant; 2011 Jun; 17(6):810-20. PubMed ID: 21220034
[TBL] [Abstract][Full Text] [Related]
7. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
Chang H; Ning Y; Qi X; Yeung J; Xu W
Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
[TBL] [Abstract][Full Text] [Related]
8. [Molecular genetic methods for the prognostic criteria in multiple myeloma].
Mikala G; Jákó J; Vályi-Nagy I
Orv Hetil; 2005 Aug; 146(32):1673-82. PubMed ID: 16149245
[TBL] [Abstract][Full Text] [Related]
9. Genomic aberrations in anaplastic multiple myeloma: high frequency of 1q21(CKS1B) amplifications.
Bahmanyar M; Qi X; Chang H
Leuk Res; 2013 Dec; 37(12):1726-8. PubMed ID: 24169086
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.
Bock F; Lu G; Srour SA; Gaballa S; Lin HY; Baladandayuthapani V; Honhar M; Stich M; Shah ND; Bashir Q; Patel K; Popat U; Hosing C; Korbling M; Delgado R; Rondon G; Shah JJ; Thomas SK; Manasanch EE; Isermann B; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2159-2164. PubMed ID: 27638366
[TBL] [Abstract][Full Text] [Related]
11. Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.
Nemec P; Zemanova Z; Greslikova H; Michalova K; Filkova H; Tajtlova J; Kralova D; Kupska R; Smetana J; Krejci M; Pour L; Zahradova L; Sandecka V; Adam Z; Buchler T; Spicka I; Gregora E; Kuglik P; Hajek R
Biol Blood Marrow Transplant; 2010 Apr; 16(4):548-54. PubMed ID: 20005965
[TBL] [Abstract][Full Text] [Related]
12. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
[TBL] [Abstract][Full Text] [Related]
14. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma.
Mendrzyk F; Korshunov A; Benner A; Toedt G; Pfister S; Radlwimmer B; Lichter P
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2070-9. PubMed ID: 16609018
[TBL] [Abstract][Full Text] [Related]
15. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma.
Chang H; Jiang N; Jiang H; Saha MN; Qi C; Xu W; Reece D
Haematologica; 2010 Sep; 95(9):1542-7. PubMed ID: 20421271
[TBL] [Abstract][Full Text] [Related]
16. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.
Neben K; Jauch A; Hielscher T; Hillengass J; Lehners N; Seckinger A; Granzow M; Raab MS; Ho AD; Goldschmidt H; Hose D
J Clin Oncol; 2013 Dec; 31(34):4325-32. PubMed ID: 24145347
[TBL] [Abstract][Full Text] [Related]
17. Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation.
Chang H; Yeung J; Xu W; Ning Y; Patterson B
Br J Haematol; 2006 Sep; 134(6):613-5. PubMed ID: 16889615
[TBL] [Abstract][Full Text] [Related]
18. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
[TBL] [Abstract][Full Text] [Related]
19. CKS1B amplification is a frequent event in cutaneous squamous cell carcinoma with aggressive clinical behaviour.
Salgado R; Toll A; Alameda F; Baró T; Martín-Ezquerra G; Sanmartín O; Martorell-Calatayud A; Salido M; Almenar S; Solé F; Pujol RM; Espinet B
Genes Chromosomes Cancer; 2010 Nov; 49(11):1054-61. PubMed ID: 20737481
[TBL] [Abstract][Full Text] [Related]
20. The survival impact of CKS1B gains or amplification is dependent on the background karyotype and TP53 deletion status in patients with myeloma.
Hao S; Lu X; Gong Z; Bassett RL; Hu S; Konoplev SN; Tang G; Li S; Xu J; Khanlari M; Lee HC; Manasanch EE; Weber DM; Orlowski RZ; Medeiros LJ; Lin P
Mod Pathol; 2021 Feb; 34(2):327-335. PubMed ID: 32908255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
